Several dozen generic drug manufacturers signed an agreement this Thursday with the Medicines Patent Pool (MPP), an organization supported by the UN, to facilitate access for 105 countries with few resources to the pill against COVID-19 from the American pharmaceutical group. Merck.
“It is a crucial step towards universal access to treatments against covid-19, which we so badly need, and we are convinced (…) that these long-awaited treatments will be quickly available in low- and middle-income countries”said Charles Gore, executive director of MPP, quoted in a statement.
According to this organization, whose purpose is to improve access to essential medicines in countries with fewer resources, the contract was signed with 27 companies from around the world, after the agreement reached with Merck last October to facilitate global access to a affordable price for molnupiravir, an oral antiviral drug against coronavirus of the American pharmaceutical group.
The agreement authorizes the companies to either manufacture the ingredients wholesale, or the medicine itself, following the strict criteria of the MPP.
These companies are based in 11 countries (Bangladesh, China, Egypt, Jordan, India, Indonesia, Kenya, Pakistan, South Africa, South Korea, and Vietnam).
RECOMMENDED VIDEO
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
